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 Introduction 
 Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a 
28-kDa glycoprotein which can be measured in periph-
eral blood by immunoassay  [1] . The clinical use of TIMP-
1 in various diseases is currently being investigated and 
has been discussed by several groups. Several studies in-
dicate that TIMP-1 may have clinical utility as tumor 
marker, since elevated levels occur in many patients suf-
fering from colorectal cancer compared to healthy indi-
viduals  [2–4] . Elevated TIMP-1 levels in colorectal cancer 
patients correlate with poorer prognosis and response to 
chemotherapy  [5, 6] . Elevated TIMP-1 levels have also 
been shown to predict worse outcome in breast cancer 
patients  [7] . Furthermore, TIMP-1 plasma levels seem to 
play an important role in metabolic disorders, such as 
diabetes and adiposity  [8–10] , as well as in patients with 
cardiac disease  [11–15] and sepsis  [16] . In addition to 
these promising investigations, some authors have pre-
sented results indicating that TIMP-1 levels differ de-
pending on pre- and perianalytical conditions  [17–22] . 
Higher levels of TIMP-1 have been measured in serum 
than in plasma, which raised suspicion that TIMP-1 is 
released by leukocytes and platelets during the coagula-
tion process and therefore plasma has been suggested to 
be the appropriate medium to measure TIMP-1 levels in 
peripheral blood  [17, 19–21] . But even in plasma, changes 
in TIMP-1 levels under different specimen handling con-
ditions have been observed  [19, 21, 22] . During our own 
investigations of TIMP-1 as a possible tumor marker, we 
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 Abstract 
 Background: Tissue inhibitor of metalloproteinases-1 (TIMP-
1) in blood might be a helpful biomarker in various diseases. 
However, various authors report that TIMP-1 is dependent 
on preanalytical procedures. Our study was performed to 
determine how storage conditions and time to centrifuga-
tion influence TIMP-1.  Materials and Methods: Twenty-six 
blood specimens were collected from each of 20 volunteers. 
Two specimens from each person were centrifuged/mea-
sured within 1 h after venipuncture and frozen at –80 ° C. 
They were thawed once or twice within 72 h. Eight speci-
mens were stored at 20 ° C in daylight, 8 at 20 ° C covered and 
8 at 4 ° C in daylight. Four of each of these 8 specimens were 
mixed once a day until centrifugation. A mixed and an un-
mixed specimen of each group was centrifuged/measured 
after 3, 6, 24 and 72 h.  Results: TIMP-1 increased after freeze/
thaw (p  ! 0.001). Mixing blood specimens more than once 
caused increased TIMP-1 (p  ! 0.001). TIMP-1 increased within 
3 h of storage (p  ! 0.001). The increase was lower in speci-
mens covered and refrigerated (p  ! 0.001).  Conclusion: 
TIMP-1 is unstable and has to be evaluated carefully. Blood 
should be centrifuged directly after venipuncture. For rou-
tine application, specimen handling must be standardized 
and carefully followed. Research should be done on speci-
mens handled identically.  Copyright © 2008 S. Karger AG, Basel 
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measured higher TIMP-1 levels in the plasma specimens 
of healthy persons than in those of patients suffering 
from colorectal cancer, which may have been caused by 
the fact that the plasma specimens of the 2 groups had not 
been handled identically prior to their measurement. 
However, our results could not be explained by the exist-
ing studies on this topic. The present study was performed 
to verify our own observations and to understand how 
TIMP-1 levels in plasma are influenced by the preana-
lytical conditions of blood specimens that they would 
likely to be exposed to in daily routine, such as time to 
centrifugation, exposure to light, mechanical manipula-
tion and freezing/thawing.
 Materials and Methods 
 Sampling 
 Blood was collected from the antecubital vein of 20 healthy 
volunteers using a tourniquet. All specimens were simultaneous-
ly taken in plastic tubes of 2.3 ml capacity containing EDTA 
(Monovette Systems; Sarstedt AG & Co., Nümbrecht, Germany). 
 Experimental Setup 
 The pattern of the trial is shown in  figure 1 . From each of the 
20 participants, 26 blood specimens were extracted into individ-
ual tubes. Two of each of the 26 specimens were processed into 
plasma and TIMP-1 was measured within 1 h after venipuncture. 
The remaining plasmas were kept frozen at –80 ° C. One of the 2 
specimens from each person was then thawed and measured 
again after 24 h and refrozen, before both were thawed and mea-
sured after 72 h. The other 24 blood specimens from each person 
were stored under different conditions prior to their centrifuga-
tion and measurement: 8 were kept at 20 ° C and exposed to day-
light, 8 were kept at 20 ° C but covered with aluminum foil and 8 
were stored at 4 ° C in the cold storage room, where they were also 
exposed to light. The impact of mechanical manipulation on the 
blood specimens was tested by mixing 4 of each of these 8 speci-
mens from all 3 storage conditions on a turntable for 30 min per 
day until centrifugation. A mixed and an unmixed specimen of 
each group was then centrifuged and measured after 3, 6, 24 and 
72 h.
 Laboratory Methods 
 All specimens were centrifuged at 2,000  g at 4 ° C for 10 min. 
The supernatant was transferred into dry plastic tubes. TIMP-1 
was measured using an automated immunoassay (Architect Sys-
tem; Abbott Diagnostics, Abbott Park, Ill., USA). To test interas-
say variation, 2 specimens of each of 3 controls with low, interme-
diate and high TIMP-1 concentrations were simultaneously mea-
sured in each run. The mean (with SD in parentheses) and 
median (with range in parentheses) TIMP-1 values were 51.1 ng/
ml (1.2) and 51.29 ng/ml (48.4–53.1) for the low controls, 103.0 
ng/ml (2.4) and 102.7 ng/ml (98.8–108.4) for the medium controls 
and 312.5 ng/ml (9.9) and 312.5 ng/ml (294.2–333.2) for the high 
controls. The coefficients of variation resulting from these data 
are 2.4%, 2.3% and 3.2%, respectively.
 Statistics 
 All statistical calculations were done using SAS (version 9.1; 
SAS Institute, Cary, N.C., USA). For comparisons of TIMP-1 lev-
els in corresponding plasma specimens, a t test was performed. 
Results were considered significant for p  ! 0.05.
 Results 
 Freezing/Thawing 
 It was found that TIMP-1 levels increased after each 
freeze/thaw cycle. The measured TIMP-1 levels and the 
differences between the thawed specimens and those 
measured directly after centrifugation are shown in  fig-
ure 2 . Significantly higher TIMP-1 values were measured 
in specimen 1 after its second freeze/thaw cycle 72 h after 
venipuncture than after the first freeze/thaw cycle 24 h 
after venipuncture (p  ! 0.0001). In contrast, TIMP-1 val-
ues in specimen 2 measured after its first thawing 72 h 
after venipuncture were not higher than those in speci-
men 1 measured after its first thawing 24 h after veni-
puncture (p = 0.71).
 Mechanical Manipulation 
 While the applied mixing procedure did not influence 
TIMP-1 levels in the specimens centrifuged and mea-
sured after 3 and 6 h, the mixed specimens stored 24 and 
72 h prior to centrifugation showed significantly higher 
TIMP-1 levels than the corresponding unmixed speci-
mens (p  ! 0.001). According to the experimental setup, 
24 h
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20°C daylight (8) Yes (4)
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 Fig. 1. Illustration of the experimental setup as described in Ma-
terials and Methods. 
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the specimens centrifuged after a storage time of 24 or
72 h had been put on the turntable 2 and 3 times, respec-
tively, while those centrifuged after 3 and 6 h had only 
been mixed once. The differences found between mixed 
and unmixed specimens are shown in  figure 3 . As the 
differences were similar under all storage conditions, all 
specimens were evaluated combined irrespective of where 
they had been kept prior to centrifugation.
 Storage Time and Conditions 
 To simplify the evaluation of the impact of storage 
time and conditions prior to centrifugation on TIMP-1 
levels, only the specimens which had not been mixed 
were considered. It was found that in all these speci-
mens, TIMP-1 levels were higher than in the specimens 
centrifuged and measured directly after venipuncture. 
Corresponding data are shown in  table 1 and  figure 4 . 
The increase was significant after all tested time inter-
vals of 3, 6, 24 and 72 h, the extent of the increase, how-
ever, varied depending on the storage conditions. TIMP-
1 levels increased significantly more in the specimens 
stored at 20 ° C than in those stored at 4 ° C and the in-
crease was significantly higher in the specimens exposed 
to light than in the covered ones. Results are shown in 
 figure 4 .
 Discussion 
 Many results have been published indicating that 
TIMP-1 may have clinical utility as a biomarker in 
colorectal cancer  [2–6] and in other diseases  [7–16] . Sev-
eral studies have shown that TIMP-1 blood levels are de-
pendent on preanalytical conditions  [17–22] . During our 
own investigations on the clinical use of TIMP-1 we made 
some unexpected observations that likely could only be 
explained by a possible bias of different specimen han-
dling used. Since the existing data on this topic could not 
explain our observations adequately, we performed the 
present study. In contrast to the results presented by Hol-
ten-Andersen et al.  [19] and Alby et al.  [21] , we measured 
increased TIMP-1 levels after each freezing and thawing 
cycle, which is in accord with our previous observations 
[unpubl. data] and which indicates that the increase in 
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p < 0.0001
0.6 (7.2)
p = 0.7
13.5 (5.3)
p < 0.0001
14.1 (8.6)
p < 0.0001  
Difference
Specimen 2,
1st thawing, 72 h
Specimen 1,
1st thawing, 24 h
Specimen 1,
1st thawing, 24 h
Specimen 2,
1st thawing, 72 h
Specimen 1,
2nd thawing, 72 h
11.2 (6.4)
p < 0.0001
25.3 (13.4)
p < 0.0001
Unfrozen
24 h 72 h
65
85
105
125
145
TI
M
P-
1 
(n
g
/m
l)
Unfrozen
Specimen 2
Specimen 1
Mean
 Fig. 2. Influence of freeze/thaw on TIMP-1 
levels in plasma: 2 of the 26 plasma speci-
mens from each person were frozen and 
thawed once (labeled specimen 2) or twice 
(labeled specimen 1) within 72 h. Figures 
are means with SD in parentheses. 
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TIMP-1 is not dependent on the storage time at –80 ° C, 
but is caused by the freezing/thawing procedure itself. 
While Alby et al.  [21] used heparin plasma instead of 
EDTA plasma and a different centrifugation mode, Hol-
ten-Andersen et al.  [19] performed their freeze/thaw 
study similar to our trial. So even if the reason for these 
different findings cannot be found, it has to be stated that 
studies on the clinical use of TIMP-1 should only be per-
formed using plasma specimens which are comparable 
regarding their preanalytical factors, such as storage time 
and number of previous freeze/thaws. Our results con-
cerning specimen handling prior to centrifugation clear-
ly show that TIMP-1 increases when whole blood speci-
mens are stored prior to their further processing into 
plasma. This phenomenon can possibly be explained by 
the degradation of platelets in these blood specimens, as 
platelets contain high concentrations of TIMP-1 as re-
ported by Cooper et al.  [23] . While in our trial the ob-
served increase was significant even after a storage time 
of 3 h, Holten-Andersen et al.  [19] only obtained a sig-
nificant increase after a storage time of 8 h in their simi-
lar trial. We cannot confirm that reliable TIMP-1 values 
can be measured when blood specimens are centrifuged 
within 8 h. Our findings rather suggest that the increase 
is a steady process and that blood specimens have to be 
centrifuged and measured immediately after venipunc-
Table 1. Time to centrifugation
Mean difference of TIMP-1 levels to directly measured specimens
after 3 h after 6 h after 24 h after 72 h
Storage at 20° C, daylight 21.0 (12.5) 28.0 (13.1) 38.5 (13.0) 45.9 (15.1)
Storage at 20° C, covered 10.0 (9.8) 18.7 (14.5) 28.7 (14.5) 39.1 (14.3)
Storage at 4° C, daylight 7.7 (6.7) 11.7 (13.3) 14.5 (13.1) 23.8 (12.1)
Figures in parentheses are SD. The differences found between TIMP-1 values in the specimens stored before 
centrifugation and those centrifuged directly after blood collection for all time intervals and storage conditions 
are shown. p < 0.001 for all obtained results.
After 72 hAfter 6 h After 24 hAfter 3 hDifference (mixed – not mixed)
<0.001<0.0010.4890.994p value
19.910.211.111.5SD
27.88.21.00.0Mean
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 Fig. 3. Mechanical manipulation: TIMP-1 
levels in all mixed specimens compared to 
those measured in the unmixed specimens 
after all tested time intervals. 
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ture in order to obtain reliable TIMP-1 values. The lack 
of significance after 8 h in the study of Holten-Andersen 
et al.  [19] might be caused by the relatively low number of 
blood donors: they only used 8 blood donors, while in our 
trial 20 persons were involved. Furthermore, the auto-
mated prototype Architect immunoassay for TIMP-1 
used in our trial provides more precise and reliable data 
than the manual ELISA kits used so far, especially when 
specimens have to be measured quickly and in several 
runs per day as necessary for the investigation of preana-
lytical biases. Additionally, we investigated the impact of 
storage temperature and exposure to light on TIMP-1 lev-
els. According to the findings of Lomholt et al.  [22] , stor-
age of the whole blood specimens in the cold storage 
room at 4 ° C could reduce the increase in TIMP-1. Simi-
larly, covering the testing tubes with aluminum foil to 
protect them from light had the same effect, even if to a 
lesser extent. These results lead to the conclusion that 
blood specimens used for the measurement of TIMP-1 
should be kept covered and refrigerated for as short as 
possible prior to their centrifugation and measurement, 
which can hardly be realized in daily clinical routine; as 
TIMP-1 levels had already increased after a storage time 
of 3 h, which was the shortest time interval tested, no 
definite recommendation regarding a maximum storage 
time can be given. We furthermore tested the impact of 
mechanical manipulation on the whole blood specimens 
as they might be exposed to when they have to be sent by 
post to the laboratory. A significant increase in TIMP-1 
values could only be found in the specimens mixed twice 
or more after 24 h or later with most of them being mac-
roscopically hemolytic. This indicates that any common-
ly used transportation of the specimens can be performed 
within 24 h without causing an increase in TIMP-1. How-
ever, considering the fact that TIMP-1 values steadily in-
crease when whole blood is stored prior to centrifugation, 
it has to be suggested that transportation of specimens 
should preferably be performed after processing them 
into plasma and placing them in secondary tubes. 
 The present study underlines the importance of a care-
ful investigation of the stability of new biomarkers and 
the need for specimen handling standards in order to ob-
tain reliable data.
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